CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
This guide compares risk profiles of index funds and bonds in retirement, helping you choose allocations that align with your comfort and goals.
28,591 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
The 2008 crisis left more than scars. Its real legacy 2008: moral hazard and policy backstops still push risk, pricin...
New to rental investing and torn between a single-family home and a duplex? This practical guide breaks down financin...
A sharp drop in Oddity Tech shares sparked questions about the health of a high-growth tech play. Even with solid qua...
Diplomacy with Iran could spark big moves in oil this week. If talks gain momentum, prices could ease; if they stall,...
Intuitive Machines stock keeps surprising investors with its steady gains. This guide breaks down the drivers, risks,...
Bittensor's TAO aims to blend AI training services with blockchain incentives. After a sharp rally, investors wonder ...
As the clean energy shift accelerates, two hydrogen-focused leaders—Bloom Energy and Plug Power—offer distinct paths ...
Antero Resources is attracting takeover chatter as major energy players weigh bids. With strong cash flow and LNG exp...
Alphabet stock already fuels your tech exposure. If SpaceX goes public, should spacex after already owning Alphabet b...
Two industry giants released mixed Q1 results, highlighting divergent paths for July. Lockheed Martin stays mission-f...
Richtech Robotics faced a dramatic sell-off last month as legal issues and a disappointing earnings report rattled in...